By staff writers

November 6, 2019 -- The U.S. Centers for Medicare and Medicaid Services (CMS) has issued its final rule for the 2020 Medicare Physician Fee Schedule, effective January 1, and pathologists have cause for relief.

The final rule, which was published on November 1, updates payment policies, payment rates, and other provisions for services based on comments from the public and interested organizations. It includes the following changes:

  • Additional telehealth services
  • Updated policies for payment rate calculations and misvalued codes
  • Changes to evaluation and management (E/M) coding and payment following recommendations by the Current Procedural Terminology (CPT) Editorial Panel and the American Medical Association Relative Value Scale (RVS) Update Committee
  • New Medicare Part B benefit for opioid treatment programs

In an analysis of the final rule, the College of American Pathologists (CAP) highlighted what it sees as advocacy victories for the specialty. Specifically, CAP highlighted two CMS proposals that would have been bad for pathology but did not make it into the final rule. The agency had originally thought that ordering physicians should determine if advanced diagnostic tests or molecular pathology tests are intended to guide treatment in the hospital outpatient setting, in which case they would be viewed as hospital services. Also, CMS was planning to remove molecular pathology tests from the laboratory date of service exception, but in the end it did not.

"The CAP disagreed and advocated for the exception to continue to apply to molecular pathology tests, highlighting the point that the tests are still not commonly performed by hospitals, as they are not always practical or cost-effective due to lower test volumes," CAP said in the November 5 issue of its Advocacy Update, which also highlighted other wins for the specialty in the final rule.

CMS plans broader coverage for NGS in breast, ovarian cancer
The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed broad national coverage for next-generation sequencing (NGS) in Medicare patients...
CAP President Dr. Patrick Godbey sees pathology in driver's seat of medicine
ORLANDO, FL - Nowadays, it's hard to think of a disease process that the clinical laboratory doesn't outright diagnose or manage. But it hasn't always...
CAP: Action on surprise medical bills may collapse, despite bipartisan support
ORLANDO, FL - Federal legislative efforts tackling surprise medical bills face an uncertain future, despite bipartisan support and the potential for billions...
CAP warns about loss of access to pathology
The College of American Pathologists (CAP) is warning that patients may lose access to pathology services through provisions of the Lower Health Care...
CAP: Surprise medical bill proposals are 'wholly inadequate'
The U.S. College of American Pathologists (CAP) expressed support for Congress in taking action against surprise medical bills related to the provision...

Copyright © 2019

Last Updated eh 11/11/2019 9:39:03 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.